Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis

  • At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients
  • New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history

Basel, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therape

/by

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis

  • At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients
  • New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history

Basel, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therape

/by

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis

  • At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients
  • New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history

Basel, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therape

/by

Novartis partners with Special Olympics World Winter Games Switzerland 2029

Novartis partners with Special Olympics World Winter Games Switzerland 2029
angilma1

/by

Full Circle: A Story of Growth, Purpose and Coming Home to Novartis

Full Circle: A Story of Growth, Purpose and Coming Home to Novartis
tavasat1

/by

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR
   
Erstes Quartal

/by

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR
   
Erstes Quartal

/by

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

First quarter

/by

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 
arcticnovartis

  • Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1
  • Rhapsido recommended in 2026 International Urticaria Guideline for all patients who remain symptomatic after H1-antihistamine treatment2
/by

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 
arcticnovartis

  • Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1
  • Rhapsido recommended in 2026 International Urticaria Guideline for all patients who remain symptomatic after H1-antihistamine treatment2
/by